Alterity Therapeutics (ATH) H1 2026 earnings summary

Executive summary

• Advanced lead asset ATH434 toward late-stage clinical development for Multiple System Atrophy (MSA), building on positive Phase 2 results and preparing for a Phase 3 trial.

• Additional analyses reinforced ATH434's efficacy and safety, with robust effects on disease progression and orthostatic hypotension symptoms.

• Expanded scientific engagement through publications and presentations at major international conferences, supporting biomarker-guided clinical development.

• Strengthened governance with new board and management appointments to support late-stage development and strategic activities.

• Raised approximately A$20 million to support regulatory, clinical, and business development activities.

Financial highlights

• Revenue from ordinary activities increased 717% year-over-year to $909,750, primarily from interest income.

• Net loss after tax rose 34% year-over-year to $9,615,849, driven by higher R&D and administrative expenses.

• R&D tax incentive income recognized at $2,803,428, up from $1,605,925 in the prior period.

• Cash and cash equivalents at period end were $49.2 million, up from $33.2 million at June 2025.

• No dividends declared or paid for the period.

Outlook and guidance

• Preparing for an End-of-Phase-2 meeting with the FDA in mid-2026 to support Phase 3 trial planning.

• Independent commercial assessment indicates a potential worldwide peak sales opportunity of US$2.4 billion for ATH434 in MSA.

• Current cash position sufficient to fund planned expenditure over the coming year; additional capital will be needed for long-term development.